ArticleFrontiers in bioengineering and biotechnology2025
Histological assessment of a novel restorative coronary artery bypass graft in a chronic ovine model.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical Serial Assessment of Virtual Physiology After Implantation of a Novel Endoluminal Resorbable Fibrillated Scaffold.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although prosthetic conduits for coronary artery bypass grafting (CABG) are increasingly needed because of the limited availability and patency of autologous conduits, no alternatives have succeeded. Methods: Sixteen sheep underwent CABG. Thirteen received a bioabsorbable polymer graft with an incorporated nitinol microskeleton (Xeltis coronary artery bypass graft [XABG]), and three received autologous saphenous vein grafts (SVG). Pathological evaluation was conducted at 12 months. Results: In the XABG group, two sheep died perioperatively; two were sacrificed at 3 months (1 occluded, 1 patent) and two at 6 months (both patent). Two more died from occlusion at 9-10 months, and five survived with patent grafts at 12 months. All SVGs remained patent for 12 months. Histology demonstrated near-complete luminal endothelialization in XABG, with increased polymer adsorption and matrix deposition. The cross-sectional area of the SVG lumen was significantly larger than XABGs (48.2 mm Conclusion: XABG demonstrated 1-year feasibility with consistent endothelialization and polymer absorption. While SVGs had better patency, they showed greater diametrical irregularity and subsequent neointimal proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.